Treatment of COVID-19 With Conestat Alfa, a Regulator of the Complement, Contact Activation and Kallikrein-Kinin System

A dysregulated immune response with hyperinflammation is observed in patients with severe coronavirus disease 2019 (COVID-19). The aim of the present study was to assess the safety and potential benefits of human recombinant C1 esterase inhibitor (conestat alfa), a complement, contact activation and...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Frontiers in immunology Ročník 11; s. 2072
Hlavní autori:	Urwyler, Pascal, Moser, Stephan, Charitos, Panteleimon, Heijnen, Ingmar A. F. M., Rudin, Melanie, Sommer, Gregor, Giannetti, Bruno M., Bassetti, Stefano, Sendi, Parham, Trendelenburg, Marten, Osthoff, Michael
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Switzerland Frontiers Media S.A 14.08.2020
Predmet:	Aged Aged, 80 and over Betacoronavirus - drug effects C1 esterase inhibitor Complement C1 - antagonists & inhibitors Complement C1 Inhibitor Protein - analysis Complement C1 Inhibitor Protein - therapeutic use complement system Coronavirus Infections - drug therapy COVID-19 Cytokine Release Syndrome - drug therapy Factor XIa - antagonists & inhibitors Female Humans Immunology inflammation kallikrein-kinin system Kallikrein-Kinin System - drug effects Kallikreins - antagonists & inhibitors Male Middle Aged Pandemics Pneumonia, Viral - drug therapy Recombinant Proteins - therapeutic use SARS-CoV-2 Viral Load - drug effects COVID-19 kallikrein-kinin system SARS-CoV-2 inflammation complement system contact activation system C1 esterase inhibitor
ISSN:	1664-3224, 1664-3224
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!